Skip to main content
Admissions guidance, study banks, and career tools — get started on Shalyam
Research News

Serotonin's Hidden Role in Heart Valve Disease

Mayur Tembhare
  1. The study was published in Science Translational Medicine in 2023 by researchers at Columbia University and other institutions.

  2. Serotonin may play a role in heart valve disease, particularly in people with degenerative mitral regurgitation (DMR).

  3. Reduced activity of the serotonin transporter can accelerate damage to mitral valves already affected by DMR.

  4. The study found that people with low levels of serotonin in their body may be more likely to experience fatigue and shortness of breath if they have DMR.

Serotonin's Hidden Role in Heart Valve Disease

Topic: Health

Researchers at Columbia University found that serotonin, a chemical messenger, may influence heart valve disease. They discovered that reduced activity of the serotonin transporter can accelerate damage to mitral valves already affected by degenerative mitral regurgitation (DMR). The study was published in Science Translational Medicine in 2023.

Serotonin is usually linked with mood, sleep, and digestion. But a recent study suggests it may also play a role in heart valve disease.

The mitral valve sits between the heart's left atrium and left ventricle. It acts like a one-way gate, keeping blood from flowing backward into the upper chamber. DMR is a common form of heart valve disease where the valve tissue degenerates, causing the thin flaps to thicken or lose their shape.

The study found that reduced activity of the serotonin transporter can accelerate damage to mitral valves already affected by DMR. This means that people with DMR may be more likely to experience fatigue, shortness of breath, and other complications if they have low levels of serotonin in their body.

Researchers at Columbia University's Department of Surgery led the work in collaboration with the Pediatric Heart Valve Center at Children's Hospital of Philadelphia (CHOP), the University of Pennsylvania, and the Valley Hospital Heart Institute. The study was supported by the National Heart, Lung, and Blood Institute.

Why It Matters

This discovery is important for Indians because heart valve disease is a growing concern in India, with many young people suffering from it. Understanding the role of serotonin in this condition can help doctors develop new treatments to prevent or slow down its progression.

Key Facts

  • The study was published in Science Translational Medicine in 2023 by researchers at Columbia University and other institutions.
  • Serotonin may play a role in heart valve disease, particularly in people with degenerative mitral regurgitation (DMR).
  • Reduced activity of the serotonin transporter can accelerate damage to mitral valves already affected by DMR.
  • The study found that people with low levels of serotonin in their body may be more likely to experience fatigue and shortness of breath if they have DMR.
  • Heart valve disease is a growing concern in India, with many young people suffering from it.

Key Terms

Serotonin
A chemical messenger that helps regulate mood, sleep, digestion, and other bodily functions.
Mitral Valve
A small structure in the heart that acts like a one-way gate to keep blood from flowing backward into the upper chamber.

Implications

This discovery is important for Indians because heart valve disease is a growing concern in India, with many young people suffering from it. Understanding the role of serotonin in this condition can help doctors develop new treatments to prevent or slow down its progression.

Source: https://www.sciencedaily.com/releases/2026/07/260711010131.htm

Journal reference:

  1. Estibaliz Castillero, Emmett Fitzpatrick, Samuel J. Keeney, Alex M. D’Angelo, Benjamin B. Pressly, Michael T. Simpson, Mangesh Kurade, W. Clinton Erwin, Vivian Moreno, Chiara Camillo, Halley J. Shukla, Vaishali V. Inamdar, Arbi Aghali, Juan B. Grau, Elisa Salvati, Itzhak Nissim, Lubica Rauova, Mark A. Oyama, Stanley J. Stachelek, Chase Brown, Abba M. Krieger, Robert J. Levy, Giovanni Ferrari. Decreased serotonin transporter activity in the mitral valve contributes to progression of degenerative mitral regurgitation. Science Translational Medicine, 2023; 15 (677) DOI: 10.1126/scitranslmed.adc9606
  2. Estibaliz Castillero, Chiara Camillo, Dov Levine, Alex M. D\'Angelo, Yaagnik Kosuri, Juan B. Grau, Robert J. Levy, Giovanni Ferrari. Serotonin transporter deficiency in mice results in an increased susceptibility to HTR2B-dependent pro-fibrotic mechanisms in the cardiac valves and left ventricular myocardium. Cardiovascular Pathology, 2025; 74: 107689 DOI: 10.1016/j.carpath.2024.107689
  3. Denisa Bianca Mercean, Raluca Tomoaia, Ioana Berindan-Neagoe, Liviuţa Budişan, Dana Pop, Adela Mihaela Șerban, Carmen Stanca Melincovici, Carmen Mihaela Mihu. Peripheral Serotonergic Activation in Severe Aortic Stenosis: A Biochemical Perspective. International Journal of Molecular Sciences, 2025; 26 (21): 10250 DOI: 10.3390/ijms262110250
  4. Dov Levine, Chiara Camillo, Estibaliz Castillero, Emre Bektik, Yaagnik Kosuri, Anthony Campbell, Cary Karcher, Abba Krieger, Liming Pei, Ting Peng, Nicole Zeak, Erfan Faridmoayer, Mark A. Oyama, Juan B. Grau, Robert J. Levy, Giovanni Ferrari. Serotonin transporter downregulation is associated with aortic stenosis, and early profibrotic remodeling is mitigated by pharmacological inhibition of HTR2B receptor. Frontiers in Cardiovascular Medicine, 2026; 13 DOI: 10.3389/fcvm.2026.1729078
  5. Anthony Campbell, Arianna Adamo, Emre Bektik, Yaagnik Kosuri, Cary Karcher, Dov Levine, Rajasekhar Ramakrishnan, Juan B. Grau, Robert J. Levy, Giovanni Ferrari. Inhibition of the serotonin transporter and risk of heart valve disease: A systematic review and meta-analysis. European Journal of Pharmacology, 2026; 1027: 178954 DOI: 10.1016/j.ejphar.2026.178954

Leave a comment

← All research

Get Exclusive Insights with Every Issue

Join Shalyam Newsletter

Stay ahead in education, research, and innovation—straight to your inbox.